Abstract 5469
Background
CD103+ Tissue-resident CD8+ T cells are previously reported as memory CD8+ T cells and thus could promote adaptive immune response. While immunotherapy shows a great potential in muscle-invasive bladder cancer (MIBC) treatment, it is urgent to discover which subgroup MIBC patients could benefit most from immunotherapy. We here tried to explore the prognostic and predictive value of CD103+ tissue-resident CD8+ T cells, and provide possible molecular explanations.
Methods
We selected 259 MIBC patients who underwent radical cystectomy between 2002 and 2014. CD103+ tissue-resident CD8+ T Cells were evaluated via immunofluorescence of CD103 and CD8 performed in our constructed tissue microarrays. Prognostic value of CD103+ CD8+ T cells in MIBC was assessed, and was further validated in TCGA-BLCA cohort using tissue-resident CD8+ T cell core signatures. 10 fresh MIBC specimens were analyzed by flow cytometry to explore the anti-tumoral immune response and immune check-point expression of tissue-resident CD8+ T cell.
Results
Patients with higher CD103+ tissue-resident CD8+ T cells infiltration had a significant better overall survival in both our study population and TCGA-BLCA cohort (HR = 0.504, 95%CI: 0.312-0.816; P = 0.005 and HR = 0.637, 95%CI: 0.444-0.913; P = 0.014). Further Cox regression indicated that CD103+ tissue-resident CD8+ T cells was an independent prognosticator in MIBC patients. Flow cytometry results revealed that CD103+ CD8+ T cells tended to express more IFN-γ and granzyme B than CD103- CD8+ T cells (P < 0.001 and P = 0.007, respectively) (n = 10). However, expression of perforin did not show significant differences between CD103+ CD8+ T cells and CD103- CD8+ T cells. We then analyzed PD-L1 and TIM3 expression in CD103+ tissue-resident CD8+ T cells. Surprisingly, there was no significant differences of PD-L1 expression between CD103+ CD8+ T cells and CD103- CD8+ T cells. Nonetheless, CD103+ CD8+ T cells had more TIM3+ phenotypes than CD103- CD8+ T cells (P = 0.034).
Conclusions
High CD103+ tissue-resident CD8+ T cells could predict better prognosis in MIBC patients. Patients with high infiltration of CD103+ tissue-resident CD8+ T cells might benefit most from anti-TIM3 immunotherapy.
Clinical trial identification
Legal entity responsible for the study
Dai, Bo.
Funding
National Natural Science Foundation of China; Shanghai Municipal Natural Science Foundation; Shanghai Municipal Commission of Health and Family Planning Program; Guide Project of Science and Technology Commission of Shanghai Municipality; Shanghai Cancer Research Charity Center.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract